Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Adaptive Trial of Four Antiviral Regimens in Mild COVID-19
NCT04532931Phase 2Completed
- Sponsor
- Shinpoong Pharma
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of artesunate + pyronaridine in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Shinpoong Pharma. Primary endpoint: Incidence of SARS-CoV-2 Clearance at Day 7. Started Sep 2020; status: completed.
02
Drugs
artesunate + pyronaridine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04532931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532931.